Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro

27 Nov 2021

Abstract excerpt

BACKGROUND: CAR T-cell therapy has been recently unveiled as one of the most promising cancer therapies in hematological malignancies. However, solid tumors mount a profound line of defense to escape immunosurveillance by CAR T-cells. Among them, cytokines with an inhibitory impact on the immune system such as IL-10 and TGFβ are of great importance: TGFβ is a pleiotropic cytokine, which potently suppresses the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34838059
DOI: 10.1186/s12967-021-03146-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitroPMID 34838059Read ↗

CRISPR/Cas9-mediated TGFβRII Disruption Enhances Anti-tumor Efficacy of Human Chimeric Antigen Receptor T Cells in VitroSemantic proximity Read ↗

Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-βSemantic proximity Read ↗

CRISPR/Cas9 edited tumor-associated immune cells in cancer immunotherapySemantic proximity Read ↗

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapySemantic proximity Read ↗

Transforming growth factor‐β signaling: Tumorigenesis and targeting for cancer therapySemantic proximity Read ↗

CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applicationsSemantic proximity Read ↗

Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapySemantic proximity Read ↗

Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapySemantic proximity Read ↗

Transforming Growth Factor-β: A Multifunctional Regulator of Cancer ImmunitySemantic proximity Read ↗

Application of Genome Editing Techniques in ImmunologySemantic proximity Read ↗

Rewiring endogenous genes in CAR T cells for tumour-restricted payload deliverySemantic proximity Read ↗

Engineering antigen-driven co-stimulation and T helper cell activity into TCR-T cells with CD8-41BB fusion receptors enhances anti-tumor activitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.